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Abstract
Background: Retention of patients on antiretroviral therapy (ART) over time is a proxy for quality of care and an outcome
indicator to monitor ART programs. Using existing databases (Antiretroviral in Lower Income Countries of the International
Databases to Evaluate AIDS and Me ´decins Sans Frontie `res), we evaluated three sampling approaches to simplify the
generation of outcome indicators.
Methods and Findings: We used individual patient data from 27 ART sites and included 27,201 ART-naive adults ($15
years) who initiated ART in 2005. For each site, we generated two outcome indicators at 12 months, retention on ART and
proportion of patients lost to follow-up (LFU), first using all patient data and then within a smaller group of patients selected
using three sampling methods (random, systematic and consecutive sampling). For each method and each site, 500 samples
were generated, and the average result was compared with the unsampled value. The 95% sampling distribution (SD) was
expressed as the 2.5
th and 97.5
th percentile values from the 500 samples. Overall, retention on ART was 76.5% (range 58.9–
88.6) and the proportion of patients LFU, 13.5% (range 0.8–31.9). Estimates of retention from sampling (n=5696) were
76.5% (SD 75.4–77.7) for random, 76.5% (75.3–77.5) for systematic and 76.0% (74.1–78.2) for the consecutive method.
Estimates for the proportion of patients LFU were 13.5% (12.6–14.5), 13.5% (12.6–14.3) and 14.0% (12.5–15.5), respectively.
With consecutive sampling, 50% of sites had SD within 65% of the unsampled site value.
Conclusions: Our results suggest that random, systematic or consecutive sampling methods are feasible for monitoring ART
indicators at national level. However, sampling may not produce precise estimates in some sites.
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Introduction
At the end of 2009, more than 5 million people were receiving
antiretroviral therapy (ART) in low- and middle-income coun-
tries,[1] out of 33.4 million people (estimated range: 31.1 million–
35.8 million) living with HIV [2,3]. This represents a 30% increase
in one year and a 13-fold increase in ART uptake in six years.
Monitoring of ART programmes is critical for understanding
when sites are under-performing and estimating the potential
impact of treatment, at the population level and for program
management at different levels of the health system. In addition,
reporting of such indicators helps to sustain national and global
commitment to monitor quality of care while expanding access to
ART and its growing use.
Many countries are still struggling to report national pro-
gramme indicators. In 2009, 70 out of 149 low- and middle-
income countries (47%) reported statistics on patient retention on
ART at 12 months and 30 (20%) at 48 months [4]. This outcome
indicator is one of several core indicators recommended to
monitor the Declaration of Commitment on HIV/AIDS during
the United Nations General Assembly Special Session on HIV/
AIDS (UNGASS) [5]. Although some countries have highly
automated information systems, many ART sites within countries
have difficulty in maintaining the registers/databases necessary to
produce these statistics. A number of factors may explain the
difficulties in generating good quality information. Many ART
programmes are relatively recent, yet facing large and rapid
increases in the number of patients starting therapy. They have
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care and reporting baseline information rather than on follow-up.
In addition to ART, HIV care includes various other components
(e.g. prevention and treatment of opportunistic infections includ-
ing tuberculosis or integration with reproductive health services)
that require regular monitoring. With the rapid expansion of ART
services and decentralisation to peripheral health centres, data
management has to occur at all levels of health service provision
and should be designed to be as simple and user-friendly as
possible in order for it to be adopted universally. Finally, ART
treatment is life-long, leading to continued workload increase due
to inclusion of new patients and continued follow-up.
In this paper we evaluated the performance of three sampling
approaches to produce two clinic and higher level indicators at 12
months: retention on ART [6] and proportion of patients lost to
follow-up, using existing databases from ART programmes in low-
and middle-income countries.
Methods
Sources of data
ART-LINC of IeDEA is a large collaborative network of HIV/
AIDS treatment programmes in low- and middle-income countries
in Africa, South America and Asia, originally funded by the
United States National Institutes of Health (Office of AIDS
Research) and the French Agence Nationale de Recherches sur le
Sida et les he ´patites virales (ANRS). It is now part of the
International epidemiological Database to Evaluate AIDS collab-
oration of the NIH (http://www.iedea-hiv.org). This network was
established in 2003 to characterize the prognosis of HIV-infected
patients treated with ART in resource-limited settings, to compare
the experience between different settings, delivery modes and types
of monitoring; and to compare outcomes with those observed in
industrialized nations [7]. Staff at the sites filled in a detailed
abstraction form using their own medical records, or downloaded
the required data from their own electronic medical records
(EMR) systems. Data were merged anonymously at the University
of Bern, Switzerland and the University of Bordeaux, France [8].
Since 2001, Me ´decins Sans Frontie `res (MSF) has provided ART
in 26 countries with a high HIV prevalence, most of them in
Africa and Asia. Basic patient individual clinical, laboratory and
treatment information are routinely collected at every clinic visit
using standardized forms. Data are continuously entered into the
Follow-up and Care of HIV Infection and AIDS (FUCHIA) EMR
software (Epicentre, Paris, France). Capacity building and
maintenance of the databases are funded by MSF and data
centralized anonymously in Epicentre – Paris, France, the
epidemiological support office of MSF [9,10].
Ethics statement
International review boards in each country have approved the
use of routinely collected programme data at all ART-LINC sites.
This study was approved by the research ethics review committee
of the World Health Organisation and the ethics review board of
Me ´decins Sans Frontie `res. The data analysed are primarily
collected for patient management and program monitoring, with
the agreement of the ministries of health of the countries. Because
of this reason, patient informed consent is not routinely requested
in all sites. All ethic boards were aware of this and approved the
secondary use of data for this analysis.
Selection of sites and indicators
For this analysis we selected all ART sites with more than 260
ART naive adults aged $15 years old starting ART in the year
2005. All databases were updated more than 12 months after the
inclusion of the last patient in 2005. We analysed the patient status
at 12 months, classified as followed on ART, dead, stopped
treatment, and lost to follow-up (LFU). Patients LFU were defined
as patients with no recorded visit for $90 days from the last visit
within the first year. Patients transferred to another ART
programme within the first 12 months of treatment were excluded
from the analysis (n=896 or 3% of the overall database).
We studied two indicators measured 12 months after ART
initiation, the proportion of patients LFU and the proportion
retained on ART.
Sampling methods
For each ART site, the required sample size was calculated,
assuming a retention at 12 months of 75% as n$[(u
2
a*N*p*(1-p))/
(D
2 * (N-1)+u
2
a*p*(1-p))] with n sample size, N total population of
each site, p expected proportion estimated at 75%, D precision
estimated at 0.05 and ua estimated at 1.96. We used the sample
required to ensure that the 95% (i.e., 1-alpha) confidence interval
of the 75% proportion had a width at least 2 times Delta where
Delta is the required precision. Three sampling methods were
considered: the random selection, systematic and consecutive
sampling. In random sampling each patient of each clinic database
had an equal probability of selection and each patient was selected
using a random number allocation. In systematic sampling, the
first patient was randomly selected and the others were drawn
from the clinic database according to a sample interval defined as
N/n until achievement of the desired sample size. In consecutive
sampling, the first patient was randomly selected, then patients
consecutively registered were selected until the achievement of the
required sample size.
Statistical analyses
We first compared estimates of the retention on ART at 12
months obtained using Kaplan-Meier methods (taking into
account the exact duration of follow-up of each patient before
treatment discontinuation) with the proportion of patients retained
on ART at 12 months (as recommended by UNGASS [5]). The
outcomes were either death, stopping ART or LFU within the first
12 months, while for patients alive and on ART follow-up was
censored at 12 months.
Thereafter all estimates were generated as proportions at 12
months as it is the usual method in routine programme
monitoring. We calculated the two indicators using first the
overall dataset and compared the proportions with those resulting
from computation in sub-samples obtained with the three
sampling methods. Indicators obtained using the full dataset are
referred to as ‘‘unsampled’’ values. For each site and for each
sampling method, 500 samples were simulated. We used the mean
of the 500 results and the 2.5
th and 97.5
th values to determine the
95% sampling distribution (SD) and compared it to the unsampled
site value. Indicators obtained using the full dataset were also
compared to those obtained with the sampling methods according
to cohort size taking the median value (870 patients) as a threshold,
type of setting (rural/urban) and the proportion of patients LFU in
the cohort (,10% versus $10%).
Combined indicators for all sites were then generated by
aggregating site specific sampling results; the estimate of the mean
was a weighted average of the proportion at each site weighted by
the sample proportion (i.e., the number of patients selected divided
by the total number of eligible patients at each site). Statistical
analyses were performed using Statistical Analysis System software
(SAS, version 9.1).
Sampling and ART Monitoring
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Twenty-seven ART sites, 22 located in Africa and five in Asia,
were included with a total of 27,201 patients treated. The number
of patients per site ranged from 378 to 4111. After 12 months on
ART 2,036 (7.5%) patients had died (range 1.9% to 16.7% across
sites), 688 (2.5%) had stopped ART (range: 0% to 8.5%) and
13.5% were LFU (range 0.8% to 31.9%) (Table 1). Estimates of
retention on ART at 12 months calculated with the proportion
and Kaplan-Meier methods were similar, at 75.9% (range 58.7%
to 88.6%) and 76.5% (58.9% to 88.6%) respectively. All following
results were generated as proportions as it is the usual method in
routine programme monitoring.
A total of 5,696 patients (20.9%; range 6.6% to 51.1% across
cohorts) were sampled. Estimates for 12-month retention on ART,
from random, systematic and consecutive sampling were 76.5%
(95% SD 75.4–77.7), 76.5% (95% SD 75.3–77.5) and 76.0% (95%
SD 74.1–78.2), respectively, compared to 76.5% for the
unsampled value (Figure 1). The sample distribution for the 500
sample iterations varied across sites. Overall, sample distribution
was wider when using consecutive sampling; the 2.5
th value was
within minus 5% of the unsampled value for 14/27 sites (51.8%)
and the 97.5
th value was within plus 5% for 21/27 sites (78%) and
ranged from 210.0% to +10.6%. Variability in sample distribu-
tion was independent of cohort size (P=0.98), urban/rural
location (P=0.99) or the proportion of patients LFU in the cohort
(P=0.81).
Similar results were observed for the proportion of patients LFU
indicator (Figure 2). The consecutive sampling method slightly
overestimated the estimates (14.0%; 95% SD 12.5–15.5) com-
Table 1. Number of patients analysed and treatment outcomes at 12 months of ART by cohort on the full dataset.
ART site Country
Number of
adults starting
ART in 2005
Number
of adults
sampled
Number of treatment outcomes at 12 months and proportion among all
adults starting ART in 2005
Deaths
ART
discontinuations
Lost to follow-
up $90 days
from last visit
Retention
on ART at
12 months
n n n% n % n% n %
Kampong Cham Cambodia 606 196 58 9.6 29 4.8 27 4.4 492 81.1
Phnom Penh Cambodia 610 196 20 3.3 52 8.5 5 0.8 533 87.4
Siem Reap Cambodia 424 172 29 6.8 17 4.0 15 3.5 363 85.6
Takeo Cambodia 491 182 45 9.2 6 1.2 16 3.2 424 86.3
Pissy Burkina-Faso 899 219 54 6.0 52 5.8 143 15.9 650 72.3
Kinshasa DRC 1065 227 178 16.7 14 1.3 86 8.1 787 73.9
Busia Kenya 860 217 55 6.4 26 3.0 73 8.5 706 82.1
Homabay Kenya 954 222 101 10.6 15 1.6 104 10.9 734 76.9
Kibera Kenya 435 174 23 5.3 25 5.7 49 11.3 338 77.7
Mathare Kenya 549 190 23 4.2 32 5.8 74 13.5 420 76.5
Chiradzulu Malawi 1599 245 150 9.4 22 1.4 186 11.6 1241 77.6
Thyolo Malawi 1359 238 172 12.7 33 2.4 121 8.9 1033 76.0
AltoMae Mozambique 1208 233 23 1.9 22 1.8 245 20.3 918 76.0
Mavalan Mozambique 1294 236 65 5.0 49 3.8 132 10.2 1048 81.0
Moatize Mozambique 278 142 15 5.4 14 5.0 12 4.3 237 85.2
Lagos Nigeria 713 206 41 5.7 12 1.7 69 9.7 591 82.9
Arua Uganda 1137 231 44 3.9 33 2.9 153 13.4 907 79.8
Kapiri Kawama Zambia 559 191 67 12.0 5 0.9 19 3.4 468 83.7
Bulawayo Zimbabwe 953 222 110 11.5 5 0.5 129 13.5 709 74.4
Murambinda Zimbabwe 428 173 68 15.9 2 0.5 14 3.3 344 80.4
Total MSF 16421 4112 1341 8.2 465 2.8 1672 10.2 12943 78.8
YRG care India 767 210 28 3.6 46 6.0 245 31.9 452 58.9
CEPREF Co ˆte d’Ivoire 1127 230 89 7.9 0 0.0 123 10.9 915 81.2
AMPATH Kenya 4111 270 277 6.7 157 3.8 618 15.0 3067 74.6
Lighthouse Malawi 2177 255 179 8.2 0 0.0 643 29.5 1355 62.2
Gugulethu South Africa 870 217 71 8.2 13 1.5 70 8.0 721 82.9
ISS Uganda 1350 238 27 2.0 1 0.1 299 22.1 1023 75.8
Connaught Zimbabwe 378 164 24 6.3 6 1.6 15 4.0 335 88.6
Total IeDEA 10780 1584 695 6.4 223 2.1 2013 18.7 7868 73.0
Total 27201 5696 2036 7.5 688 2.5 3685 13.5 20811 76.5
doi:10.1371/journal.pone.0013899.t001
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was wider than intervals obtained with random (13.5%; 95% SD
12.6–14.5) and systematic sampling (13.5%; 95% SD 12.6–14.3).
Discussion
When paper records are used at ART sites, programme
monitoring often relies on transferring key information from
patients’ medical records into paper registers or electronic
databases and aggregating the information at regular periods for
reporting and interpretation of findings at all levels of the health
system. Maintaining accurate medical records for all patients at
every contact is essential to ensure quality of care and patient
management, but the subsequent transfer of information for the
purpose of programme monitoring could be limited to a sample of
patients rather than the full cohort to reduce workload. Sampling
has already been used for HIV/AIDS care program monitoring
[11] but precision of the results obtained had not been assessed.
Sampling has also been used to determine outcomes among
patients LFU by tracing in the community [12,13].
Figure 1. Proportion of patients on ART at 12 months: comparison of estimates according to the sampling technique (median,
inter-quartile range, 10–90% deciles and minimum maximum) with the unsampled value (dotted line).
doi:10.1371/journal.pone.0013899.g001
Figure 2. Proportion of patients lost to follow-up at 12 months: comparison of estimates according to the sampling technique
(median, inter-quartile range, 10–90% deciles and minimum maximum) with the unsampled value (dotted line).
doi:10.1371/journal.pone.0013899.g002
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patients retained on ART and of patients LFU at 12 months.
These statistics were obtained first with the overall dataset without
sampling, then after applying three sampling strategies. Many
international indicators, including the UNGASS indicators, are
indeed calculated only at a national level and do not require
exhaustive site-specific data. Our sampling strategies performed
well on the dataset combining patient data collected in 27 sites.
Overall estimates were similar independently of the sampling
method used. Sampling performed particularly well when
indicators were calculated in the full dataset while differences in
estimates and sample distribution were more variable when
analysed at site level. For 12-month retention on ART, the
sample distribution obtained by consecutive sampling was wider
compared to random and systematic sampling methods with a
maximum distribution of 610% of the unsampled value. Whereas
not directly comparable, the cluster sampling method used to
monitor immunization coverage in children was developed three
decades ago for sampling results to range within 610% from the
population value and has always been recommended since then;
although 17% of sampling results fell outside these limits, the
method was considered to perform well enough for programmatic
purposes [14].
Patient life-long retention on ART is of growing concern in the
rapid scale-up of large treatment programmes[4,15–17]. An
analysis in South Africa showed a deterioration in retention on
ART over time with an increasing proportion of patients LFU
among those enrolled during the most recent years. It was in part
related to the large increase in patients but the authors also
discussed the burden on health informatics systems and admin-
istrative errors leading to misclassification in LFU [15]. Improving
and maintaining simple and standardised monitoring systems
capturing true treatment outcomes is part of the strategies
recommended to better document and therefore improve patient
retention on ART [17].
The workload required to ensure good quality of ART cohort
monitoring is substantial for both paper-based and electronic
systems. It also increases with the size and follow-up of the cohort.
EMR systems allow the systematic and sometimes automated
production of statistical indicators using information from all
patients, but they are resource-intensive, as they require data
clerks, training, and system maintenance[18]. A review of EMR
systems used in 21 ART sites in low- and middle-income countries
reported a median proportion of missing data for key information
of 10.9% [19]. Missing data declined with training on data-
management and with the number of hours spent by data-clerks in
the maintenance of the databases. The number of hours necessary
to reduce the proportion of missing information below 10% was
estimated at 10 hours per week per 100 patients on ART. Time is
also required to set the system up and expand it throughout a
country. Some countries are moving towards a national EMR
system; SmartCare is an EMR system currently deployed in
Zambia, Ethiopia and South Africa [20]. However, in the current
situation where international donors are not providing additional
financial support, countries where an insufficient proportion of
persons in need of ART are receiving treatment may prioritize
employing and training additional clinical and laboratory staff to
provide patient care over investing resources to develop and
maintain an EMR system.
In the absence of EMR that would support the analyses of full
cohort data, sampling approaches could thus potentially limit the
workload in longitudinal monitoring and reinforce the long-term
sustainability of monitoring systems at local and national levels.
Moreover, retention on ART is to be analysed not only at 12
months but also for subsequent years of follow-up to document
trends in retention on ART over time. The number of yearly end-
points to analyse will therefore increase with the maturity of the
programs. Sampling might be particularly useful in ART sites with
a large number of patients initiating ART annually. Based on our
analysis, the minimum sample size for a cohort of 500 patients
would be 184, 224 for a cohort of 1000 and 252 for a cohort of
2000 patients. Consecutive sampling would probably be the most
practical approach for the selection of patients. A number of
countries are currently collecting retrospective patient data to
generate longitudinal indicators once or twice a year; abstraction
of information and calculation of indicators could potentially be
performed using a sample of patients starting on ART in each
calendar year. Sampling could be also piloted as an interim
strategy while implementing EMR and/or could be used for
purpose of quality control.
The present evaluation was based on existing databases in well
resourced sites that receive support to maintain complete, quality-
assured medical records. Thus the performance observed for
sampling is not directly generalisable to a national programme.
Performance of sampling strategies will depend on the accuracy or
completeness of medical records and/or registers and on the level
of organisation of the filing system. This evaluation did not address
the issue of additional support that may be required in many ART
sites where data are missing or inaccurately recorded. Sampling
may also be difficult to implement in routine monitoring and needs
a standardised and sustainable method for the long-term
comparability of results. Personnel at site level may not be
confident with results produced by sampling. Pilot projects to
produce and validate monitoring indicators from sampling and to
quantify related workload are therefore needed to complement this
work.
In conclusion, generation of the two longitudinal indicators we
studied in a sample of patients appeared to be a potentially useful
method for programme monitoring at national level, based on
available data from the ART-LINC of IeDEA and MSF cohort
collaborations. However, the feasibility of this approach needs to
be evaluated at country level and the accuracy of estimates based
on sampling should be evaluated at site level in countries interested
in this approach.
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